Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinical features of 31 patients with ovarian cancer who had previous platinum resistant relapse and were retreated with platinum

From: Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes

Clinical Characteristics Number of cases (%)
Age (years old)
  < 65 21 (67.7)
  > 65 10 (32.3)
Histology
 High grade serous carcinoma 21 (67.7)
 Endometrioid 1 (3.2)
 Clear cell carcinoma 1 (3.2)
 Undifferentiated carcinoma 3 (9.7)
 Carcinosarcoma 1 (3.2)
 Mixed 1 (3.2)
Family history of ovarian or breast cancer
 No 19 (61.3)
 Yes 9 (29.0)
Number of previous treatment lines
 2 10 (32.3)
 3 7 (22.6)
 4 4 (12.9)
 5 6 (19.4)
 6 3 (9.7)
 8 1 (3.2)
Platinum free interval (months)
  < 12 21 (67.7)
  > 12 10 (32.3)
Primary platinum resistance*
 No 12 (38.7)
 Yes 19 (61.3)
Chemotherapy with platinum rechallenge
 Platinum + taxane 15 (48.4)
 Platinum + gemcitabina 13 (41.9)
 Platinum + doxorubicin 1 (3.2)
 Platinum + ifosfamide 1 (3.2)
 Monotherapy 1 (3.2)
  1. *Primary platinum resistant disease was defined as a first recurrence with a platinum free interval less than 6 months. Patients without primary platinum resistant recurrence, presented platinum resistant disease at second or later recurrences